Publication: Adverse cardiac events related to hydroxychloroquine prophylaxis and treatment of COVID-19
Program
KU-Authors
KU Authors
Co-Authors
Zengin, Rehile
Sarıkaya, Zeynep Tuğçe
Karadağ, Nalan
Çuhadaroğlu, Çağlar
Kocagöz, Sesin
Publication Date
Language
Type
Embargo Status
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Coronavirus disease 2019 (COVID-19) was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020. The disease is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). The measures to contain the spread of the disease such as social-distancing, hand hygiene, contact tracing, and isolation of persons suspected or confirmed to have the infection have been considered to be largely effective. No specific drugs for COVID-19 have been proven to be effective currently for either prophylaxis or treatment. However, hydroxychloroquine (HCQ) was suggested as one of the choices of the drug, despite the lack of evidence-based information. We present three case reports of cardiovascular adverse effects, with respect to its propensity to cause QT interval prolongation and potentially serious cardiac arrhythmias.
Source
Publisher
DOC Design and Informatics
Subject
Covid-19, Cardiac, Kovid-19, Kardiyak
Citation
Has Part
Source
Infectious Diseases and Clinical Microbiology (Online)
Book Series Title
Edition
DOI
10.36519/idcm.2020.0012